

***Welcome to the 2007
Cardiovascular Biomarker and
Surrogate Endpoint
Symposium***

**A COLLABORATIVE APPROACH
TO BIOMARKERS**

Sponsorship

Funding for this symposium is also made possible through the generosity of the following organizations as unrestricted educational grants

- AstraZeneca
- Merck Research Laboratories
- Servier
- Novartis
- CSL Ltd.
- LipoScience Inc.
- Wyeth
- General Electric Healthcare
- F. Hoffmann-La Roche Ltd.
- Siemens Medical Solutions
- Pfizer Inc. and Pfizer Canada
- Boehringer-Ingelheim
- Schering-Plough
- VisualSonics
- AtCor Medical

Symposium Co-Sponsors



**BRIGHAM AND
WOMEN'S HOSPITAL**
A Teaching Affiliate of Harvard Medical School



**National Heart
Lung and Blood Institute**
People Science Health

International Partnership for

CRITICAL MARKERS OF DISEASE

CMOD

**U. S. Department of Health and Human Services
U. S. Food and Drug Administration
Center for Food Safety and Applied Nutrition**



Montreal Heart Institute
Coordinating Center

MHICC

***Welcome to the 2007
Cardiovascular Biomarker and
Surrogate Endpoint
Symposium***

**A COLLABORATIVE APPROACH
TO BIOMARKERS**

Biomarkers are Essential

Improve understanding of disease and risk factors

Develop better diagnostics and screening tools

Develop better prevention and treatment strategies

Monitor safety and efficacy

Decrease resource utilization

2007 CV Biomarkers and Surrogate Endpoint Symposium

- Biomarkers are essential
- Education is essential
- Communication is essential
- ***Collaborative efforts are essential***

Symposium Objectives

- Provide scientifically rigorous and balanced information
- Facilitate the cooperative exchange of ideas
- Identify areas for collaborative efforts

October 17th

Biomarker Insights, Advances and Practical
Considerations

General Session 8:00 – 1:00

Parallel Breakout Sessions (1:30-5:00)

Session 1 – Cardiovascular Imaging – Salon D

Session 2 – Lipids and Inflammation – Salon A

October 18th

Biomarker Models and Applications – Best Practices
for Validation and Decision-Making
General Session 8:00 – 1:00

Parallel Breakout Sessions (1:30-5:00)

- 1 - Genomics/Proteomics/Metabolomics
- 2 - Trial Design, Drug/Diagnostic Dvpt
Strategies/Case Studies

October 19th

Priorities, Perspectives and Challenges

Regulators – FDA, EMEA, Health Canada
FDA Pilot Process for Biomarker
Qualification

Housekeeping Details

- All sessions are being recorded for posting at www.cmod.org
- No personal recording devices in meeting rooms
- CME forms at registration table
- Evaluation forms at registration table

Participant Demographics

- Countries: US, Canada, the Netherlands, United Kingdom, Switzerland, France, Japan and China
- Approximately 250 participants from 100+ different organizations
- Organizations:
 - 43% Pharma/Biotech
 - 20% Government
 - 18% Academic
 - 10% Diagnostic
 - 9% Other (genetics, food, insurance, undisclosed)

2007 Cardiovascular Biomarker and Surrogate Endpoint Symposium

A COLLABORATIVE APPROACH TO BIOMARKERS

“Nature, when she adds difficulties, adds
brains.”

- Ralph Waldo Emerson